Capricor Therapeutics Faces Class Action Lawsuit Over Securities Violations

Capricor Therapeutics Faces Class Action Lawsuit

Capricor Therapeutics, Inc., a biotechnology firm, is under scrutiny following a class action lawsuit alleging violations of securities laws. The lawsuit primarily concerns misleading statements made regarding the firm's deramiocel drug candidate's pursuit of FDA approval. According to the DJS Law Group, which is leading the charge on behalf of investors, these public announcements did not align with the adverse findings from Capricor's Phase 2 HOPE-2 trial.

Background of the Case

The complaint alleges that Capricor provided investors with false information about the progress of its drug candidate. Although the company's statements suggested strong momentum toward receiving FDA approval, internal data from clinical trials reportedly told a different story.

The class action period is set from October 9, 2024, to July 10, 2025, with a deadline for participation in the lawsuit by September 15, 2025. Shareholders who acquired shares during this timeframe are encouraged to contact the DJS Law Group to determine if they may serve as lead plaintiffs, though such an appointment is not required to participate in any recovery efforts.

Key Allegations

The allegations center on the premise that investors were provided with optimistic updates regarding the drug candidate while being oblivious to negative data that had emerged from preliminary trials. This misrepresentation, according to the lawsuit, constitutes a direct violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The DJS Law Group is urging affected shareholders to act by registering for participation in the case to secure their rights to potential recovery.

What Investors Should Know

For investors impacted by the price decline of Capricor's shares due to these alleged securities violations, the DJS Law Group has assured that registration for participation will enroll them in a monitoring system. This tool will keep them posted on significant developments in the case without any associated costs or obligations.

The DJS Law Group specializes in enhancing investor returns through a focus on securities class actions and corporate governance litigation. Their expertise extends to managing litigation claims that are valuable assets for their clients, which include some of the largest hedge funds worldwide.

Conclusion

As the case progresses, shareholders of Capricor Therapeutics, Inc. should consider taking legal action to safeguard their rights and explore avenues for recovery. Whether pursuing lead plaintiff status or opting to be part of the broader class action, being proactive is essential. Those interested can reach out to the DJS Law Group for more details on how to participate.

For more information, potential investors may contact:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

This situation urges shareholders to remain vigilant about their investments and the legal implications that can arise from public company disclosures. Participating in this class action is one way victims of alleged securities fraud can seek justice and potentially recover losses incurred during the troubling period.